Sriram S. Narsipur

Sriram S. Narsipur

Auto-generated profile, based on publicly available information

Sriram S. Narsipur

SUNY Upstate Medical University, Syracuse, NY, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2011 in Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ASAnurag Singh
Anurag Singh
SNS. S. Narsipur
S. S. Narsipur
The evidence for conversion from brand name to generic equivalent cyclosporine is conflicting. Cyclosporine is a narrow therapeutic-range drug for which small variations in exposure may have severe clinical consequences for transplant patients. There is currently a lack of comparative outcome data relating to the pharmacokinetics of the reference formulation, Neoral, and generic formulations in transplant recipients. A major common concern is the potential inability to attain similar trough levels, an issue that can be easily corrected by ongoing therapeutic drug monitoring to ensure that the new steady state falls within an intended target range. Prospective clinical studies investigating the efficacy and safety of generic formulations in bothde novoand long-term transplant patients are also awaited. Until further evidence is available on the conversion of transplant patients to or between generic formulations of cyclosporine, any transfer to a different cyclosporine formulation should be undertaken with close supervision. The best available information to date, however, does not support the frequently held but unsubstantiated belief that generic preparations of immunosuppressive drugs are not as effective as brand names or that conversion from brand to generic is associated with significant danger. This paper attempts to initiate a discussion of these issues.

19 September 2014 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
DHDavid Haughey
David Haughey
SNSriram S. Narsipur
Sriram S. Narsipur
Background: Posterior reversible leukoencephalopathy syndrome (PRES) is characterized by an acute neurologic dysfunction coupled with characteristic findings on brain imaging. PRES occurs in the setting of hypertensive emergencies, eclampsia and as a neurotoxic effect of immunosuppressive agents. While overwhelmingly reversible without residual deficits when promptly recognized, vague symptomatology may delay the diagnosis of PRES. Results/Summary: A 50-year-old man who had undergone a recent kidney transplant was admitted to our clinic due to multiple episodes of seizure. He had no prior history of seizures or alcoholism. His transplantation had been without complication; he was discharged and given prednisone, tacrolimus, mycophenolate, acyclovir, trimethoprim-sulfamethoxazole, atenolol and enalapril. On the day of presentation, he experienced a severe headache, blurred vision and tonic-clonic seizure-like activity. His neurologic examination was limited by sedation, although no focal deficits were evident. Laboratory studies were unremarkable. A lumbar puncture revealed normal opening pressure, negative Gram stain, benign CSF analysis and India ink preparation. An MRI of the brain revealed bilateral enhancing parietal-occipital lesions, seen prominently on FLAIR sequence. Tacrolimus and all other medications were continued. The patient remained afebrile and normotensive and was extubated on the second hospital day. The patient reported no neurologic symptoms and was discharged on the third hospital day after a full recovery. Conclusions: While the outcome of PRES is typically benign, a delay in diagnosis may lead to permanent neurologic deficits, and misdiagnosis can be lethal. The cornerstone of treatment is removal of the offending agent or treatment of the underlying etiology. A clinical picture of headache, visual abnormalities, altered mentation and seizures is sufficient to prompt an empiric discontinuation of agents known to cause PRES. Calcineurin inhibitors such as tacrolimus are known to cause PRES, and in our patient, discontinuation led to a complete clinical resolution.

6 September 2006 in Nephrology
Verified
Journal Article
Closed access
PDF file
POPhilip T Ondocin
Philip T Ondocin
SNSriram S Narsipur
Sriram S Narsipur

1 February 2004 in Clinical Nephrology
Verified
Journal Article
Closed access
SNS.S. Narsipur
S.S. Narsipur
Fiber bundle volume (FBV) is an important determinant of dialyzer re-use efficiency. This measurement is performed after the dialyzer has been pressure cleaned and may underestimate the degree of clotted fibers a patient actually encounters while on dialysis. Real-time online measure of FBV has been validated using an ultrasound dilution method and the Transonic HD01 monitor (Ithaca, NY, USA). Thirty-one stable chronic hemodialysis patients were studied during the first hour and then during the last 30 minutes of a typical dialysis session. Ultrasound velocity curves using a saline bolus were recorded by flow dilution sensors placed directly on the blood tubing using methods described previously. Blood volume within the dialyzer compartment was determined using a mathematical extrapolation of the measured transit time for a bolus of saline to pass through the dialyzer. These data were compared to FBV obtained using a Seartronics DRS4 (Fresinius, Walnut Creek, CA, USA) reprocessing machine both before and after the same dialysis session. At onset of treatment mean FBV by ultrasound was 100.0 +/- 2.7 ml and was unchanged at the end of the session at 100.0 +/- 3.1 ml (p = 0.49). Before a dialysis session, mean FBV measured on the DRS4 reprocessing machine was 123.5 +/- 2.1 ml and was unchanged following cleaning after dialysis at 121.7 +/- 2.0 ml (p = 0.20). The correlation coefficient between methods was 0.78. FBV did not change during a dialysis session using an online real-time measure. The results of this study do not support concerns that hemodialysis patients may experience considerably less efficient dialysis than standard FBV determination would suggest due to undetected clotting.

1 July 2003 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SNSriram S. Narsipur
Sriram S. Narsipur
OPOrjan W. Peterson
Orjan W. Peterson
RSRobert Smith
Robert Smith
TBTimothy D. Bigby
Timothy D. Bigby
SPSampath Parthasarathy
Sampath Parthasarathy
RBRoland C. Blantz
Roland C. Blantz
Significant glomerular vasoconstriction and production of reactive oxygen species has been known to occur with exposure to anti–glomerular basement membrane antibody (AGBM-Ab) in the rat model. Previously published studies have demonstrated that such effects can be reduced by therapy with phentolamine, an α-adrenergic antagonist. It was hypothesized that antioxidant pretreatment with water-soluble probucol would improve glomerular hemodynamics 60 to 90 min after the administration of AGBM-Ab. These relationships were examined with both in vivo renal micropuncture and in vitro studies in rats. Single-nephron GFR (SNGFR) decreased markedly in untreated rats after AGBM-Ab as a result of afferent and efferent arteriolar vasoconstriction with consequent reductions in nephron plasma flow (SNPF) and decreases in the glomerular ultrafiltration coefficient (LpA). Basal SNGFR was increased, and SNGFR was significantly higher after AGBM-Ab in probucol-treated versus untreated rats. This finding was due solely to higher values for SNPF and prevention of afferent arteriolar constriction. A reduction in LpA after AGBM-Ab was not prevented by probucol treatment. In vitro analyses of glomeruli revealed reduced myeloperoxidase activity in antioxidant-treated rats. Lipoxygenase activity and leukotriene products, however, were not changed by antioxidant therapy, yet vasoconstriction was prevented. H2O2 generation before and after formyl-methionyl-leucyl-phenylalanine stimulation was significantly reduced before and after AGBM-Ab in glomeruli harvested from rats that were treated with the antioxidant. Antioxidant therapy in this model of AGBM-Ab injury did not prevent reductions in LpA, an index of glomerular membrane damage, but did prevent afferent arteriolar vasoconstriction. Reactive oxygen species generation was reduced by probucol. The specific mechanisms whereby antioxidant therapy ameliorates glomerular hemodynamic effects will be defined in additional studies and is likely to involve either enhanced vasodilator or diminished vasoconstrictor activity. E-mail narsipur@upstate.edu

24 December 2002
Verified
Journal Article
Closed access
SNSriram S Narsipur
Sriram S Narsipur
PSPaul F Shanley
Paul F Shanley